Literature DB >> 1731400

Effects of (R)-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse.

T B Knudsen1, R S Winters, S K Otey, M R Blackburn, M J Airhart, J K Church, R G Skalko.   

Abstract

The viability of early mouse embryos is acutely sensitive to (R)-deoxycoformycin (pentostatin), a tight-binding inhibitor of adenosine deaminase (ADA). Previous studies have shown that a single 5-mg/kg dose on day 7 (plug = day 0) of gestation fully inhibits uteroplacental ADA activity within 0.5 h; causes massive cell death in the neural plate and primary mesenchyme by 6 h, major craniofacial anomalies by day 10, and resorption by day 12 (Knudsen et al., '89; Airhart et al., '91). The present study has examined further the developmental toxicity and early effects of this inhibitor on ADA metabolism. (R)-Deoxycoformycin was administered to pregnant CD-1 (ICR) mice as a single intraperitoneal dose of 0.5-10 mg/kg total body weight on days 6-11 of gestation. The major adverse effect, early resorption, was dose dependent and specific to day 7-8 exposure. Treatment with 5 mg/kg on day 7 resulted in 85% resorptions, 15% malformations, and a 24% reduction in mean fetal weight, whereas the same dose of (S)-deoxycoformycin had no effect. Levels of adenosine and 2'-deoxyadenosine, which are the endogenous substrates of ADA, were monitored in the embryo/decidual unit (E/D) by reversed-phase high-performance liquid chromatography (RP-HPLC). In response to the inhibitor, both nucleosides increased transiently in the antimesometrial compartment (antimesometrial decidua + embryo). Peak levels (Cmax) of adenosine and 2'-deoxyadenosine were dose dependent over the range tested (0.05-10 mg/kg). Exposure to 5 mg/kg on day 7 raised adenosine levels within 0.5 h to 42-fold over the basal level of 0.06 nmol/mg protein. There was an even stronger effect on 2'-deoxyadenosine levels, which were elevated 674-fold over the detection limit of 0.0005 nmol/mg protein. Direct exposure to the inhibitor in serum-free E/D culture produced similar results: 50 microM (R)-deoxycoformycin within 1 h raised adenosine levels 26-fold and 2'-deoxyadenosine levels 410-fold. In vivo studies also showed a general correlation between embryolethality and the length of adenine nucleoside pool expansion, apparent for exposure on day 7, 8, or 9 but not on day 6, suggesting that the embryo becomes sensitive to adenosine or 2'-deoxyadenosine once the neural plate has formed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731400     DOI: 10.1002/tera.1420450109

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  21 in total

1.  A role of erythrocytes in adenosine monophosphate initiation of hypometabolism in mammals.

Authors:  Isadora Susan Daniels; Jianfa Zhang; William G O'Brien; Zhenyin Tao; Tomoko Miki; Zhaoyang Zhao; Michael R Blackburn; Cheng Chi Lee
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

2.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

3.  Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73).

Authors:  R Resta; S W Hooker; A B Laurent; S M Jamshedur Rahman; M Franklin; T B Knudsen; N L Nadon; L F Thompson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 4.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

5.  Adenine nucleotide-mediated regulation of hepatic PTP1B activity in mouse models of type 2 diabetes.

Authors:  Xiao Yang; Yang Zhao; Qi Sun; Yunxia Yang; Yan Gao; Wenhao Ge; Junhao Liu; Xi Xu; Dan Weng; Shiming Wang; Jianfa Zhang
Journal:  Diabetologia       Date:  2019-08-13       Impact factor: 10.122

6.  9-(2'-Deoxy-2'-Fluoro-β-d-Arabinofuranosyl) Adenine Is a Potent Antitrypanosomal Adenosine Analogue That Circumvents Transport-Related Drug Resistance.

Authors:  Farahnaz Ranjbarian; Munender Vodnala; Khalid J H Alzahrani; Godwin U Ebiloma; Harry P de Koning; Anders Hofer
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

7.  A1 adenosine receptors mediate hypoxia-induced ventriculomegaly.

Authors:  Christopher P Turner; Meltem Seli; Laura Ment; William Stewart; Henglin Yan; Bjorn Johansson; Bertil B Fredholm; Michael Blackburn; Scott A Rivkees
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-15       Impact factor: 11.205

8.  Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansion.

Authors:  Denise A Carbonaro; Xiangyang Jin; Daniel Cotoi; Tiejuan Mi; Xiao-Jin Yu; Dianne C Skelton; Frederick Dorey; Rodney E Kellems; Michael R Blackburn; Donald B Kohn
Journal:  Blood       Date:  2008-03-20       Impact factor: 22.113

9.  Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway.

Authors:  Michael R Blackburn; Chun G Lee; Hays W J Young; Zhou Zhu; Janci L Chunn; Min Jong Kang; Suman K Banerjee; Jack A Elias
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

10.  Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.

Authors:  Denise A Carbonaro; Xiangyang Jin; Xingchao Wang; Xiao-Jin Yu; Nora Rozengurt; Michael L Kaufman; Xiaoyan Wang; David Gjertson; Yang Zhou; Michael R Blackburn; Donald B Kohn
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.